Breast Milk Stem Cells and Maternal Microchimerism: Mechanisms and Clinical Implications

Abstract

Human breast milk is recognized as a living, cell-rich fluid that provides viable maternal cells along with supplementary nutrients and soluble immunomodulators. It contains heterogeneous populations of mesenchymal, hematopoietic, epithelial, and pluripotent-like stem/progenitor cells that can differentiate into derivatives of all three germ layers in vitro. Preclinical studies have shown that milk-derived cells can survive gastrointestinal passage, enter the neonatal circulation, and reside in multiple organs, such as the brain, liver, and immune tissues. These cells express organ-specific markers and contribute to maternal microchimerism. Studies on the neonatal gut and blood-brain barrier show that a narrow early-life window exists in which breast milk stem cells can access systemic and, in experimental models, central nervous system compartments. This window is established by immature intestinal barrier properties, age-dependent differences in neurovascular interfaces, and homing cues induced by injury or inflammation. It has been suggested that these cells may contribute to organ maturation and tissue repair. Maternal cell transfer during lactation has been associated with the expansion of regulatory T cells, tolerance to non-inherited maternal antigens, stronger vaccine-induced T-cell responses, and, in certain circumstances, improved infection control. These results collectively support the idea that maternal cellular transfer contributes to the development of infant immunity during the early stages of life. This review provides a concise summary of the phenotype and origin of breast milk stem cells, their trafficking and contribution to maternal microchimerism, neonatal immune development, and the clinical implications for the health of both infants and mothers.